NVDA
NVIDIA
-- 149.430 TSLA
Tesla
-- 411.050 FUBO
FuboTV
-- 5.060 AMD
Advanced Micro Devices
-- 129.550 PLTR
Palantir
-- 75.920 
Update PT $11
$Ardelyx (ARDX.US)$ has recently announced that their product, XPHOZAH (tenapanor), is ready for shipment to pharmacies. This product is intended for use as an add-on therapy for adult chronic kidney disease patients undergoing dialysis who have not responded adequately to phosphate binders or cannot tolerate any dose of phosphate binder therapy. The novel mechanism of action of XPHOZAH, which operates as a sodium hydrogen exchange 3 (NHE3) inhibitor, offers a unique alternative pathway to reduce serum phosphorus, especially for patients who are intolerant to phosphate binders.
Furthermore, the unique mechanism of action is seen as a justification for the premium pricing of XPHOZAH at $2,960/month, compared to the $1,400-2,400 monthly price range estimates for currently approved phosphate binders. Arce also considered the company’s existing commercial infrastructure, which includes a dedicated nephrology sales team of 60 reps covering about 8,000 high-prescribing nephrology health care providers. This infrastructure is predicted to contribute significantly to XPHOZAH’s early commercial traction. Lastly, Arce’s rating is also influenced by the projected net sales of XPHOZAH, which are estimated to reach $1.3M in 4Q23 for about 1.5 months of sales.![]()
Furthermore, the unique mechanism of action is seen as a justification for the premium pricing of XPHOZAH at $2,960/month, compared to the $1,400-2,400 monthly price range estimates for currently approved phosphate binders. Arce also considered the company’s existing commercial infrastructure, which includes a dedicated nephrology sales team of 60 reps covering about 8,000 high-prescribing nephrology health care providers. This infrastructure is predicted to contribute significantly to XPHOZAH’s early commercial traction. Lastly, Arce’s rating is also influenced by the projected net sales of XPHOZAH, which are estimated to reach $1.3M in 4Q23 for about 1.5 months of sales.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
103074861 : why so good news still no upside?
Trytosaveabit OP 103074861 : I wish I could answer that totally! Some of it is short sellers! But also now big buy volume coming in! Wish I had a better answer for you? GL![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
103074861 : what is target price?
TQ
Trytosaveabit OP 103074861 : PT for my on a DT is 6+ But as a long hold I believe the PT in a year 13+ GL![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")